Patient outcome
. | Values . | . | |
|---|---|---|---|
. | CR patients . | Non-CR patients . | |
| No. patients | 36 | 35 | |
| Neutrophil engraftment | |||
| No. patients evaluable | 35 | 32 | |
| Median time to ANC greater than 0.5 × 109/L, d (range) | 18 (11-25) | 18 (8-33) | |
| Platelet engraftment | |||
| No. patients evaluable | 35 | 24 | |
| Median time to platelet count greater than 50 × 109/L, d (range) | 21 (12-76) | 26 (12-288) | |
| Donor cell chimerism, median % (range)* | 99 (95-100) | 99 (67-100) | |
| Acute GvHD, no. (%) | |||
| No. patients evaluable | 35 | 32 | |
| Grade II-IV | 8 (23) | 20 (63) | |
| Grade III-IV | 8 (23) | 8 (25) | |
| Chronic GvHD, no. (%) | |||
| No. patients evaluable | 34 | 25 | |
| Limited disease | 11 (32) | 2 (8) | |
| Extensive disease | 6 (18) | 8 (25) | |
| Early death, 0-15 d after transplantation, no. (%) | 1 (3) | 3 (9) | |
| Death not related to relapse or disease progression, no. (%) | 3 (8) | 13 (37) | |
| Relapse, no. (%) | 6 (17) | 16 (46) | |
| Death with relapsed or progressive disease, no. (%) | 3 (8) | 15 (43) | |
| Alive and well in CR, no. (%) | 30 (83) | 6 (17) | |
| Alive with controlled disease, no. (%) | 0 | 1 (3) | |
. | Values . | . | |
|---|---|---|---|
. | CR patients . | Non-CR patients . | |
| No. patients | 36 | 35 | |
| Neutrophil engraftment | |||
| No. patients evaluable | 35 | 32 | |
| Median time to ANC greater than 0.5 × 109/L, d (range) | 18 (11-25) | 18 (8-33) | |
| Platelet engraftment | |||
| No. patients evaluable | 35 | 24 | |
| Median time to platelet count greater than 50 × 109/L, d (range) | 21 (12-76) | 26 (12-288) | |
| Donor cell chimerism, median % (range)* | 99 (95-100) | 99 (67-100) | |
| Acute GvHD, no. (%) | |||
| No. patients evaluable | 35 | 32 | |
| Grade II-IV | 8 (23) | 20 (63) | |
| Grade III-IV | 8 (23) | 8 (25) | |
| Chronic GvHD, no. (%) | |||
| No. patients evaluable | 34 | 25 | |
| Limited disease | 11 (32) | 2 (8) | |
| Extensive disease | 6 (18) | 8 (25) | |
| Early death, 0-15 d after transplantation, no. (%) | 1 (3) | 3 (9) | |
| Death not related to relapse or disease progression, no. (%) | 3 (8) | 13 (37) | |
| Relapse, no. (%) | 6 (17) | 16 (46) | |
| Death with relapsed or progressive disease, no. (%) | 3 (8) | 15 (43) | |
| Alive and well in CR, no. (%) | 30 (83) | 6 (17) | |
| Alive with controlled disease, no. (%) | 0 | 1 (3) | |
ANC indicates absolute neutrophil count; GvHD, graft-versus-host disease.
Within 2 months of transplantation